Skip to main content

Screening Ligands by X-ray Crystallography

  • Protocol
  • First Online:
Structural Genomics and Drug Discovery

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1140))

Abstract

X-ray crystallography is an invaluable technique in structure-based drug discovery, including fragment-based drug discovery, because it is the only technique that can provide a complete three dimensional readout of the interaction between the small molecule and its macromolecular target. X-ray diffraction (XRD) techniques can be employed as the sole method for conducting a screen of a fragment library, or it can be employed as the final technique in a screening campaign to confirm putative “hit” compounds identified by a variety of biochemical and/or biophysical screening techniques. Both approaches require an efficient technique to prepare dozens to hundreds of crystals for data collection, and a reproducible way to deliver ligands to the crystal. Here, a general method for screening cocktails of fragments is described. In cases where X-ray crystallography is employed as a method to verify putative hits, the cocktails of fragments described below would simply be replaced with single fragment solutions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041–3046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Davies TG, Tickle IJ (2012) Fragment screening by X-ray crystallography. Top Curr Chem 317:33–59

    Article  CAS  PubMed  Google Scholar 

  3. Broennimann C, Eikenberry EF, Henrich B et al (2006) The PILATUS 1 M detector. J Synchrotron Radiat 13(Pt 2):120–130

    Article  CAS  PubMed  Google Scholar 

  4. Verlinde CLMJ, Kim H, Bernstein BE et al (1997) Antitrypanosomiasis drug development based on structures of glycolytic enzymes. In: Veerapandian P (ed) Structure-based drug design. Marcel Dekker, New York, pp 365–394

    Google Scholar 

  5. Bosch J, Robien MA, Mehlin C et al (2006) Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem 49:5939–5946

    Article  CAS  PubMed  Google Scholar 

  6. Nienaber VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105–1108

    Article  CAS  PubMed  Google Scholar 

  7. Davies DR, Begley DW, Hartley RC et al (2011) Predicting the success of fragment screening by X-ray crystallography. Methods Enzymol 493:91–114

    Article  CAS  PubMed  Google Scholar 

  8. Davies DR, Mamat B, Magnusson OT et al (2009) Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem 52(15):4694–4715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. CSGID/SSGCID (2008) X-ray crystal structure metrics for infectious disease. http://www.csgid.org/csgid/pages/sg_metrics

  10. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biol Crystallogr 60:2126–2132

    Article  Google Scholar 

  11. Davies DR, Staker BL, Abendroth JA et al (2011) An ensemble of structures of Burkholderia pseudomallei 2,3-bisphospho-glycerate-dependent phosphoglycerate mutase. Acta Crystallogr Sect F Struct Biol Cryst Commun 67(Pt 9):1044–1050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hassell AM, An G, Bledsoe RK et al (2007) Crystallization of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 63(Pt 1):72–79

    Article  CAS  PubMed  Google Scholar 

  13. Geremia S, Campagnolo M, Demitri N et al (2006) Simulation of diffusion time of small molecules in protein crystals. Structure 14(3):393–400

    Article  CAS  PubMed  Google Scholar 

  14. Begley DW, Hartley RC, Davies DR et al (2011) Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei. J Struct Funct Genomics 12(2):63–76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Douglas R. Davies .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Davies, D.R. (2014). Screening Ligands by X-ray Crystallography. In: Anderson, W.F. (eds) Structural Genomics and Drug Discovery. Methods in Molecular Biology, vol 1140. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-0354-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0354-2_23

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-0353-5

  • Online ISBN: 978-1-4939-0354-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics